Cardiovascular

FDA approves new treatment for genetic coagulation disorder

On Dec. 18, the U.S. Food and Drug Administration (FDA) approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have congenital Factor XIII A-subunit deficiency. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares